Abiomed Makes Its Case For Impella In High-Risk Angioplasty Cases

Abiomed and its PROTECT II trial principal investigator say they are confident that a partial analysis of the halted study presented April 3 will be enough to get Impella-based circulatory support into cardiology guidelines as a recommended tool for high-risk angioplasties.